What is the recommended management for a skilled nursing facility resident with recurrent yeast (candidal) infections?

Management of Recurrent Yeast Infections in Skilled Nursing Facility Residents

For SNF residents with recurrent yeast infections, chronic suppressive therapy with fluconazole 100 mg three times weekly is strongly recommended, combined with aggressive identification and correction of predisposing factors. 1

Initial Assessment and Site-Specific Treatment

The first critical step is determining the anatomical site(s) of infection, as this dictates both acute treatment and suppressive strategies:

Oropharyngeal Candidiasis (Thrush)

• Mild disease: Clotrimazole troches 10 mg 5 times daily OR miconazole mucoadhesive buccal 50-mg tablet once daily for 7-14 days 1
• Moderate-severe disease: Oral fluconazole 100-200 mg daily for 7-14 days 1
• Denture-related: Must include denture disinfection in addition to antifungal therapy 1

Esophageal Candidiasis

• Oral fluconazole 200-400 mg daily for 14-21 days 1
• For recurrent esophagitis specifically: chronic suppressive therapy with fluconazole 100-200 mg three times weekly 1

Vulvovaginal Candidiasis

• Topical antifungal agents for uncomplicated cases 1
• For recurrent infections: fluconazole 100 mg three times weekly as chronic suppression 1

Urinary Candidiasis

• Critical: Remove indwelling bladder catheter if feasible 1
• For fluconazole-susceptible organisms: oral fluconazole 200 mg daily for 2 weeks 1
• Treatment generally NOT recommended unless high-risk for dissemination (neutropenic patients, very low birth weight infants, or patients undergoing urologic procedures) 1

Chronic Suppressive Therapy Strategy

The evidence strongly supports that chronic suppressive therapy is usually unnecessary, BUT when required for patients with recurrent infections, fluconazole 100 mg three times weekly is the recommended regimen. 1 This represents a strong recommendation with high-quality evidence from the 2016 IDSA guidelines.

Addressing Predisposing Factors (Critical for Success)

The pathogenicity of Candida is relatively low; recurrent infections indicate underlying predisposing conditions that MUST be addressed 2:

Medical/Systemic Factors to Evaluate:

• Diabetes mellitus: Optimize glycemic control
• Immunosuppression: Review medications (corticosteroids, immunosuppressants)
• Antibiotic exposure: Minimize broad-spectrum antibiotic use
• Nutritional status: Assess for malnutrition
• HIV status: If positive, antiretroviral therapy is strongly recommended to reduce recurrence 1

Local/Environmental Factors:

• Indwelling devices: Remove urinary catheters, central lines when feasible 1
• Moisture/maceration: Address incontinence, improve hygiene assistance
• Dentures: Ensure proper cleaning and disinfection protocols 1
• Personal hygiene: Many SNF residents have medical conditions affecting their ability to maintain hygiene 3

Special Consideration: Candida auris in SNF Settings

If dealing with Candida auris (an emerging concern in SNFs), the approach differs significantly:

• This is a critical priority pathogen with high transmission potential in SNF environments 4, 3, 5, 6
• Requires contact precautions and enhanced environmental disinfection 3, 5
• Colonized residents may not require treatment unless symptomatic infection develops 3, 5
• Decolonization therapy may be attempted, though evidence for effective regimens is limited 3
• Infection control is paramount: proper placement of affected residents, frequent environmental disinfection with appropriate agents 3

Algorithm for Fluconazole-Refractory Disease

If recurrent infections persist despite fluconazole suppression:

1. Obtain fungal cultures and susceptibility testing to guide therapy 7

2. For fluconazole-refractory oropharyngeal disease:

   • Itraconazole solution 200 mg once daily OR posaconazole suspension 400 mg twice daily for 3 days then 400 mg daily (up to 28 days) 1
   • Alternatives: voriconazole 200 mg twice daily OR amphotericin B deoxycholate oral suspension 1

3. For severe refractory disease: Consider IV echinocandin (caspofungin, micafungin, or anidulafungin) 1

Common Pitfalls to Avoid

• Do not treat asymptomatic candiduria unless patient is neutropenic, very low birth weight infant, or undergoing urologic procedures 1
• Do not assume all positive Candida cultures indicate infection - Candida species are normal inhabitants of skin and mucosa; positive culture alone doesn't confirm infection 2
• Do not neglect catheter removal - this is as important as antifungal therapy for urinary and bloodstream infections 1
• Do not overlook environmental factors in SNF settings - transmission and reinfection from contaminated surfaces is a real concern, especially with C. auris 4, 3, 6

Infection Control and Stewardship

The 2025 global guideline emphasizes antifungal stewardship as an essential component 7. For SNF settings:

• Routine infectious diseases consultation is strongly recommended for invasive candidiasis 7
• Establish protocols for appropriate antifungal use
• Monitor local epidemiology and resistance patterns 7, 8
• Ensure effective communication between SNF, hospitals, and health authorities for outbreak management 3